Verrica Pharmaceuticals Inc logo

VRCA

Verrica Pharmaceuticals Inc

$3.62

Earnings Summary

Revenue
$0.43Mn
Net Profits
$-8.47Mn
Net Profit Margins
-1965.2%

Highlights

Revenue:

Verrica Pharmaceuticals Inc’s revenue fell -96.41% since last year same period to $0.43Mn in the Q1 2022. On a quarterly growth basis, Verrica Pharmaceuticals Inc has generated +Inf% jump in its revenue since last 3-months.

Net Profits:

Verrica Pharmaceuticals Inc’s net profit fell -804.91% since last year same period to $-8.47Mn in the Q1 2022. On a quarterly growth basis, Verrica Pharmaceuticals Inc has generated 11.22% jump in its net profits since last 3-months.

Net Profit Margins:

Verrica Pharmaceuticals Inc’s net profit margin fell -25094.84% since last year same period to -1965.2% in the Q1 2022. On a quarterly growth basis, Verrica Pharmaceuticals Inc has generated NaN% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Verrica Pharmaceuticals Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.32
EPS Estimate Current Year
-0.32

Highlights

EPS Estimate Current Quarter:

Verrica Pharmaceuticals Inc’s earning per share (EPS) estimates for the current quarter stand at -0.32 - a 31.91% jump from last quarter’s estimates.

EPS Estimate Current Year:

Verrica Pharmaceuticals Inc’s earning per share (EPS) estimates for the current year stand at -0.32.

Key Ratios

Key ratios of the Verrica Pharmaceuticals Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.31
Return on Assets (ROA)
-0.25
Return on Equity (ROE)
-1.07
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Verrica Pharmaceuticals Inc’s earning per share (EPS) fell -675% since last year same period to -0.31 in the Q1 2022. This indicates that the Verrica Pharmaceuticals Inc has generated -675% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Verrica Pharmaceuticals Inc’s return on assets (ROA) stands at -0.25.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Verrica Pharmaceuticals Inc’s return on equity (ROE) stands at -1.07.

Dividend Per Share (DPS):

Verrica Pharmaceuticals Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-09
-0.47
-0.31
34.04%

Company Information

Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica's late-stage product candidate, VP-102, is in development to treat molluscum contagiosum (molluscum), common warts and external genital warts, three of the largest unmet needs in medical dermatology. Verrica is also developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts. The Company has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatologic oncology conditions.

Organisation
Verrica Pharmaceuticals Inc
Headquarters
West Chester, Pennsylvania, US
Employees
29
Industry
Health Technology
CEO
Ted White